These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1369713)

  • 1. Effects of naftidrofuryl on the contraction and proliferation of cultured myocytes evoked by serotonin.
    Bodin P; Travo P
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S25-8. PubMed ID: 1369713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl.
    Maloteaux JM; Haiech J; De Campeneere D; Berta P; Vidal N
    Arzneimittelforschung; 1986 Aug; 36(8):1194-8. PubMed ID: 3022761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of constriction of cerebral arterioles in vivo by naftidrofuryl. Action against serotonin and dinoprost.
    Rosenblum WI
    Arzneimittelforschung; 1987 May; 37(5):495-7. PubMed ID: 3476118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftidrofuryl inhibits contractions to serotonin in intact and de-endothelialized cerebral arteries in vitro.
    Oudart N
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S45-8. PubMed ID: 1369718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of naftidrofuryl on platelet-induced vasospasm in vitro. Role of antiserotonergic actions.
    Verheggen R; Schrör K
    Arzneimittelforschung; 1993 Mar; 43(3):330-4. PubMed ID: 8489562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases.
    Wiernsperger NF
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S37-43. PubMed ID: 7517475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibition of the spasmogenic effect of exogenous and endogenous serotonin on isolated blood vessels by naftidrofuryl].
    Verheggen R; Schrör K
    Vasa Suppl; 1988; 24():5-10. PubMed ID: 3212604
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate.
    Sharma SK; Zahradka P; Chapman D; Kumamoto H; Takeda N; Dhalla NS
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1475-81. PubMed ID: 10454527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serotonin antagonism and uterine activity].
    Lechner W; Sölder E; Kölle D
    Z Geburtshilfe Perinatol; 1991; 195(6):260-1. PubMed ID: 1776315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation.
    Hollenberg NK; Nie Q
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S36-9. PubMed ID: 1369716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of naftidrofuryl, a serotonergic antagonist, on erythrocyte aggregation.
    Nordt FJ; Jack W; Coull BM
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S29-32. PubMed ID: 1369714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin-induced contractility in human saphenous vein is inhibited by naftidrofuryl.
    Vashisht R; Sian M; Sharp EJ; Leathard HL; O'Malley MK
    Br J Surg; 1992 Nov; 79(11):1154-6. PubMed ID: 1467887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of naftidrofuryl on PGF2 alpha, U 46.619, 5-HT and thromboxane A2 (TXA2) induced vasoconstriction.
    Verheggen R; Schrör K
    Biomed Biochim Acta; 1988; 47(10-11):S264-7. PubMed ID: 3248112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet aggregation after naftidrofuryl application in vitro and ex vivo.
    Kirsten R; Erdeg B; Moxter D; Hesse K; Breidert M; Nelson K
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):81-4. PubMed ID: 7757315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic treatment with naftidrofuryl attenuates the development of vascular hypersensitivity to serotonin in the spontaneously hypertensive rat.
    Thorin E; Capdeville C; Trocklé G; Wiernsperger N; Atkinson J
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S54-7. PubMed ID: 1369720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys.
    Endemann D; Schweda F; Stubanus M; Ittner KP; Fischereder M; Kammerl MC; Krämer BK
    J Cardiovasc Pharmacol; 2002 Jan; 39(1):1-8. PubMed ID: 11743222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Deleterious cardiac effects of serotonin in myocardial ischemia: role of naftidrofuryl].
    Kioueh I; Mosnier M; Bui-Xuan B; Frassati D; Descotes J; Timour Q
    Ann Cardiol Angeiol (Paris); 2001 Jun; 50(4):229-38. PubMed ID: 12555598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of serotonergic neuronal systems in the anti-amnesic action of naftidrofuryl oxalate.
    Nabeshima T; Ichihara K; Tohyama K; Murase K; Suzuki T; Kameyama T
    Eur J Pharmacol; 1991 Nov; 205(1):55-61. PubMed ID: 1811997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure.
    Qvigstad E; Brattelid T; Sjaastad I; Andressen KW; Krobert KA; Birkeland JA; Sejersted OM; Kaumann AJ; Skomedal T; Osnes JB; Levy FO
    Cardiovasc Res; 2005 Mar; 65(4):869-78. PubMed ID: 15721867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of naftidrofuryl on peroxidation of serum and erythrocyte membrane lipids in patients with insulin-dependent diabetes mellitus].
    Kubatiev AA; Balashova TS; Smirnova VIu; Strokov IA; Konstantinovskaia TA
    Biull Eksp Biol Med; 1996 Sep; 122(9):338-41. PubMed ID: 8974495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.